Breaking News Instant updates and real-time market news.

TMO

Thermo Fisher

$213.03

-4.34 (-2.00%)

, UNH

UnitedHealth

$241.25

-1.71 (-0.70%)

10:11
05/15/18
05/15
10:11
05/15/18
10:11

Cooperman's Omega exits Zynga in Q1, adds Thermo Fisher and UnitedHealth

Leon Cooperman's Omega Advisors disclosed in a regulatory filing its holdings as of March 31, 2018. Omega made 30 new buys during the first quarter, including, by size of position, Thermo Fisher (TMO), UnitedHealth (UNH), Andeavor (ANDV), Bristol-Myers Squibb (BMY) and Brunswick (BC).The fund exited 17 positions during the quarter, including by size of previous position, Zynga (ZNGA), MGM Resorts (MGM), Expedia (EXPE), Ball Corp. (BLL) and CBS (CBS). Omega increased its stake in 19 holdings, including by size, United Continental (UAL), Citi (C), Ocwen Financial (OCN), Ashland (ASH) and HRG Group (HRG). The fund reduced its stake in 26 holdings, including Shire (SHPG), Ally Financial (ALLY), Wells Fargo (WFC), Facebook (FB) and AerCap (AER). Omega's top holdings as of March 31, in order of size, were United Continental, Alphabet Class A (GOOGL), AMC Networks (AMCX), First Data (FDC) and Microsoft (MSFT).

TMO

Thermo Fisher

$213.03

-4.34 (-2.00%)

UNH

UnitedHealth

$241.25

-1.71 (-0.70%)

ANDV

Andeavor

$141.15

-0.99 (-0.70%)

BMY

Bristol-Myers

$51.90

-0.11 (-0.21%)

BC

Brunswick

$61.04

0.1 (0.16%)

ZNGA

Zynga

$3.91

-0.095 (-2.37%)

MGM

MGM Resorts

$32.28

-0.03 (-0.09%)

EXPE

Expedia

$113.24

-1.37 (-1.20%)

BLL

Ball Corp.

$37.89

-0.47 (-1.23%)

CBS

CBS

$54.65

1 (1.86%)

UAL

United Continental

$67.28

0.64 (0.96%)

C

Citi

$72.78

0.15 (0.21%)

OCN

Ocwen

$4.58

-0.03 (-0.65%)

ASH

Ashland

$74.43

-0.25 (-0.33%)

HRG

HRG Group

$11.42

-0.48 (-4.03%)

SHPG

Shire

$170.05

1.67 (0.99%)

ALLY

Ally Financial

$27.15

0.34 (1.27%)

WFC

Wells Fargo

$55.12

0.64 (1.17%)

FB

Facebook

$184.05

-2.63 (-1.41%)

AER

AerCap

$55.35

-0.13 (-0.23%)

GOOGL

Alphabet Class A

$1,088.54

-18.03 (-1.63%)

AMCX

AMC Networks

$56.81

-0.13 (-0.23%)

FDC

First Data

$19.58

-0.06 (-0.31%)

MSFT

Microsoft

$96.46

-1.58 (-1.61%)

  • 15

    May

  • 15

    May

  • 17

    May

  • 18

    May

  • 20

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 30

    May

  • 03

    Jun

  • 04

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 26

    Jun

  • 10

    Jul

  • 21

    Dec

TMO Thermo Fisher
$213.03

-4.34 (-2.00%)

02/01/18
LEER
02/01/18
NO CHANGE
Target $239
LEER
Outperform
Thermo Fisher price target raised to $239 from $200 at Leerink
Leerink analyst Puneet Souda raised his price target for Thermo Fisher to $239 from $200 on the back of now higher guide reflected in his estimates and valuation. The analyst reiterates an Outperform rating on the shares as he believes the company is a Life Science Tools leader with an unmatched scale, access to multiple growing end markets and now has a CDMO arm.
01/31/18
COWN
01/31/18
NO CHANGE
Target $220
COWN
Outperform
Thermo Fisher well positioned for 2018 upside, says Cowen
Cowen analyst Doug Schenkel believes Thermo Fisher is well positioned to generate upside in 2018 given its strong free cash flow generation and likelihood of M&A. The analyst said its solid Q4 results has built confidence in the outlook for growth. Schenkel reiterated his Outperform rating and $220 price target on Thermo Fisher shares.
01/09/18
WELS
01/09/18
NO CHANGE
Target $260
WELS
Outperform
Illumina price target raised to $260 from $250 at Wells Fargo
Wells Fargo analyst Tim Evans raised his price target for Illumina (ILMN) to $260 from $250 after the company delivered a host of positive updates, namely a positive pre-announce of Q4 revenue, above-consensus revenue and EPS guidance for 2018, the official launch of Firefly, the launch of faster library prep consumables, and a collaboration with Thermo Fisher (TMO) to run AmpliSeq on Illumina instruments. The analyst reiterates an Outperform rating on Illumina's shares.
01/09/18
CLVD
01/09/18
NO CHANGE
CLVD
Cleveland Research expects meaningful upside in Q4 for Thermo Fisher
Cleveland Research's said checks indicate Thermo Fisher demand remained strong through year-end and sees an opportunity for 2018 growth to accelerate further.
UNH UnitedHealth
$241.25

-1.71 (-0.70%)

04/18/18
CANT
04/18/18
NO CHANGE
Target $300
CANT
Overweight
UnitedHealth price target raised to $300 from $280 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for UnitedHealth to $300 citing yesterday's "strong" Q1 results. Government membership growth remains strong while Optum's growth momentum continues, Halper tells investors in a post-earnings research note. He reiterates an Overweight rating on UnitedHealth.
04/18/18
OPCO
04/18/18
NO CHANGE
Target $276
OPCO
Outperform
UnitedHealth price target raised to $276 from $260 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for UnitedHealth to $276 from $260 after the company produced another "strong" quarter, with all business lines contributing. The analyst reiterates an Outperform rating on the shares.
04/18/18
BERN
04/18/18
NO CHANGE
Target $275
BERN
Outperform
UnitedHealth price target raised to $275 from $259 at Bernstein
Bernstein analyst Lance Wilkes raised his price target for UnitedHealth to $275 from $259 after the company reported "solid" Q1 results, driven by "strong" Optum earnings and "strong" government membership growth. The analyst reiterates an Outperform rating on the shares.
04/18/18
FBCO
04/18/18
NO CHANGE
Target $270
FBCO
Outperform
UnitedHealth price target raised to $270 from $260 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for UnitedHealth to $270 from $260 following quarterly results. The analyst reiterates an Outperform rating on the shares.
ANDV Andeavor
$141.15

-0.99 (-0.70%)

05/14/18
05/14/18
DOWNGRADE

Neutral
Andeavor downgraded to Neutral after takeover pact at JPMorgan
As previously reported, JPMorgan analyst Phil Gresh downgraded Andeavor (ANDV) to Neutral citing the proposed takeover by Marathon Petroleum (MPC).
05/14/18
JPMS
05/14/18
DOWNGRADE
JPMS
Neutral
Andeavor downgraded to Neutral from Overweight at JPMorgan
05/10/18
SBSH
05/10/18
DOWNGRADE
SBSH
Neutral
Andeavor downgraded to Neutral from Buy at Citi
Citi analyst Prashant Rao downgraded Andeavor (ANDV) to Neutral citing the proposed takeover by Marathon Petroleum (MPC). The analyst is constructive on the merger.
05/08/18
WELS
05/08/18
DOWNGRADE
WELS
Market Perform
Andeavor downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Roger Read downgraded Andeavor (ANDV), which has agreed to be acquired by Marathon Petroleum (MPC).
BMY Bristol-Myers
$51.90

-0.11 (-0.21%)

05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.
04/27/18
LEHM
04/27/18
NO CHANGE
Target $55
LEHM
Equal Weight
Bristol-Myers price target lowered to $55 from $65 at Barclays
Barclays analyst Geoff Meacham lowered his price target for Bristol-Myers Squibb to $55 following the company's Q1 results. Bristol reported solid results, but questions over Opdivo growth levers loom, Meacham tells investors in a post-earnings research note. He believes questions regarding Opdivo's overall role in front-line non-small-cell lung carcinoma are likely to continue "muddle the investment case for the stock." The analyst keeps an Equal Weight rating on Bristol-Myers.
04/27/18
04/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Hold at Stifel with analyst Scott Devitt acknowledging that he was wrong to have stuck with his recent view on Facebook following its first earnings report. 2. Microsoft (MSFT) upgraded to Overweight from Neutral at JPMorgan with analyst Mark Murphy saying the global movement toward multi-cloud architectures will benefit Microsoft's Azure. 3. Bristol-Myers (BMY) upgraded to Market Perform from Underperform at BMO Capital with analyst Alex Arfaei saying his concerns around the uncertainty of Opdivo sales erosion are mostly priced in, anticipating a 7% sales growth for the drug in 2019 and hoping for "more competitive" 1L-NSCLC readout that the recently disappointing IO data. 4. Nike (NKE) upgraded to Buy from Hold at HSBC. 5. Intel (INTC) upgraded to Market Perform from Underperform at Bernstein with analyst Stacy Rasgon citing the company's "very strong" Q1 report. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/27/18
BMOC
04/27/18
UPGRADE
Target $47
BMOC
Market Perform
Bristol-Myers upgraded to Market Perform at BMO Capital on balanced risk/reward
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Bristol-Myers to Market Perform from Underperform and kept his $47 price target. The analyst says that his concerns around the uncertainty of Opdivo sales erosion are mostly priced in, anticipating a 7% sales growth for the drug in 2019 and hoping for "more competitive" 1L-NSCLC readout that the recently disappointing IO data. Arfaei further states that the risk-reward around the stock price is now "more balanced".
BC Brunswick
$61.04

0.1 (0.16%)

03/05/18
KING
03/05/18
UPGRADE
KING
Buy
Brunswick upgraded to Buy from Neutral at CL King
03/06/18
IMPC
03/06/18
NO CHANGE
Target $78
IMPC
Outperform
Imperial sees 'substantial upside potential' in Brunswick, ups target to $78
Imperial Capital analyst George Kelly raised his price target for Brunswick to $78 from $70 and maintains an Outperform rating on the shares. The company's businesses will command better valuation following the recently announced fitness spin-off, Kelly tells investors in a research note. He sees a favorable near-term outlook, undervalued business segments and "substantial upside potential."
03/05/18
RHCO
03/05/18
NO CHANGE
Target $78
RHCO
Buy
Brunswick price target raised to $78 from $68 at SunTrust
SunTrust analyst Michael Swartz raised his price target on Brunswick Corp to $78 citing his more positive view of the Engine segment after a more detailed sum-of-the-parts analysis. Swartz adds that the near-term risk-reward model appears to be attractive amid the strong performance in the wake of the recent consumer spin-offs for Marine and Fitness businesses. The analyst keeps his Buy rating on Brunswick, stating that the company is likely to be insulated from macro volatility, while its pension liability could be reduced with this year's planned contributions.
04/13/18
RILY
04/13/18
NO CHANGE
Target $80
RILY
Buy
Brunswick price target raised to $80 from $68 at B. Riley FBR
B. Riley FBR analyst Eric Wold raised his price target for Brunswick to $80 from $68 and reiterates a Buy rating on the shares ahead of the Q1 results. The analyst believes strengthening Marine division trends provide an attractive set-up into the Fitness division spin-off.
ZNGA Zynga
$3.91

-0.095 (-2.37%)

03/28/18
PIPR
03/28/18
NO CHANGE
PIPR
Overweight
Video game publisher weakness brings buying opportunity, says Piper Jaffray
Investor concerns around the popularity of "Fortnite" and lack of specific near-term catalysts has created a buying opportunity for shares of video game publishers, Piper Jaffray analyst Michael Olson tells investors in a research note. He believes the issues facing the group are short-term, while long-term characteristics continue to improve. The analyst highlights the group's growing digital revenue mix, increasing visibility and improving free cash flow characteristics. Olson believes video game multiples can move higher and keeps Overweight ratings on Activision Blizzard (ATVI), Electronic Arts (EA), Take-Two Interactive (TTWO) and Zynga (ZNGA). Take-Two and EA are the analyst's current favorite names.
02/08/18
BARD
02/08/18
NO CHANGE
Target $4
BARD
Neutral
Zynga results demonstrate ongoing turnaround, says Baird
Baird analyst Colin Sebastian said Zynga reported Q4 results above expectations, which he views as demonstrating the company's turnaround is continuing. The analyst said the result were fueled by healthy mobile growth and its user metrics continue to improve. Sebastian noted the guidance was below expectations and so he maintained his Neutral rating and $4 price target on Zynga shares.
05/03/18
BARD
05/03/18
NO CHANGE
Target $4
BARD
Neutral
Zynga strategic plan appears on track, says Baird
Baird analyst Colin Sebastian said Zynga management's recent execution has been superb, but in order for the shares to move higher he believes the company needs to replicate the live service success experienced with CSR2 and Words With Friends 2. Sebastian noted the second half of the year has a weighted release slate and maintained his Neutral rating and $4 price target on Zynga shares.
01/03/18
01/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Itron (ITRI) initiated with a Strong Buy at Raymond James. 2. Extreme Networks (EXTR) initiated with an Outperform at JMP Securities. 3. Flex Pharma (FLKS) resumed with a Buy at Roth Capital. 4. Zynga (ZNGA) initiated with an Outperform at Consumer Edge. 5. Bank of the Ozarks (OZRK) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MGM MGM Resorts
$32.28

-0.03 (-0.09%)

04/23/18
SUSQ
04/23/18
UPGRADE
SUSQ
Positive
MGM Resorts upgraded to Positive from Neutral at Susquehanna
05/14/18
JEFF
05/14/18
NO CHANGE
JEFF
Jefferies says Penn National, Caesars among winners from sports gaming ruling
After the Supreme Court ruled that the PASPA provision prohibiting state authorization of organized sports gambling violates the tenth amendment, Jefferies analyst David Katz reiterated his view on which companies are positioned to be key beneficiaries of the decision. He continues to identify Penn National (PENN) and Caesars (CSR) as among the top winners in terms of casino operators, followed by Eldorado Resorts (ERI), Churchill Downs (CHDN), Boyd Gaming (BYD), Monarch Casino (MCRI), and MGM Resorts (MGM). He also sees "location-agnostic" suppliers Scientific Games (SGMS) and International Game (IGT) as winners, Katz tells investors.
05/07/18
JEFF
05/07/18
NO CHANGE
Target $43
JEFF
Buy
MGM analyst meeting should move shares higher, says Jefferies
Jefferies analyst David Katz expects shares of MGM Resorts to react positively to Thursday's analyst meeting. The analyst thinks the presentation will focus on growth and capital allocation. He reiterates a Buy rating on MGM with a $43 price target.
04/26/18
JEFF
04/26/18
NO CHANGE
JEFF
Buy
MGM Resorts pullback a buying opportunity, says Jefferies
Jefferies analyst David Katz views the post-earnings pullback in shares of MGM Resorts as a buying opportunity. The analyst views the report as a neutral for the stock given the pressure in Las Vegas.
EXPE Expedia
$113.24

-1.37 (-1.20%)

04/27/18
KEYB
04/27/18
NO CHANGE
Target $140
KEYB
Overweight
Expedia results 'solidly better than feared,' says KeyBanc
KeyBanc analyst Brad Erickson Expedia's Q1 results were "solidly better than feared" as he believes third-party data providers' room-night estimates heading into the report "skewed sentiment way too negative." While noting that Q2 room-night comps are tougher, he said comps get easier through the second half and Erickson thinks the setup for hotel additions remains favorable. He raised his price target on Expedia to $140 from $125 and keeps an Overweight rating on Expedia shares.
04/26/18
DADA
04/26/18
NO CHANGE
Target $5.5
DADA
Neutral
Trivago price target lowered to $5.50 from $7.30 at DA Davidson
DA Davidson analyst Tom White lowered his price target on Trivago to $5.50 after the company's Q1 results, citing the 3% decline in revenues and lowered FY18 guidance. White says the investors should particularly monitor Trivago's revenue diversification efforts, with the progress thus far seen as limited as Booking Holdings (BKNG) and Expedia (EXPE) accounted for 76% of sales in the quarter. Given the limited visibility and a "fluid" monetization landscape, White keeps his Neutral rating on Trivago.
04/27/18
PIPR
04/27/18
NO CHANGE
Target $2300
PIPR
Overweight
Booking Holdings price target raised to $2,300 from $2,100 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Booking Holdings (BKNG) to $2,300 ahead of the company's Q1 results on May 9. The analyst sees potential for upside based on Europe stability throughout Q1 and favorable results from Expedia (EXPE), Olson tells investors in a pre-earnings research note. For Q2, the analyst expects "typical conservative guidance, perhaps slightly below Street consensus" that already factors in an easy currency-neutral bookings growth comp for the quarter. Olson maintains an Overweight rating on Booking Holdings.
04/30/18
MKMP
04/30/18
NO CHANGE
Target $122
MKMP
Neutral
Expedia price target raised to $122 from $101 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Expedia to $122 after its Q1 earnings beat, saying room night growth rate of 15% was also solid thanks in part to the timing of Easter relative to last year. Sanderson adds that bookings and revenues are also trending ahead of the company's internal and also consensus expectations. The analyst keeps his Neutral rating on Expedia, noting the company is a "strong number two in an important Internet vertical" and should maintain its in-line performance.
BLL Ball Corp.
$37.89

-0.47 (-1.23%)

12/15/17
VERT
12/15/17
UPGRADE
VERT
Buy
Ball Corp. upgraded to Buy on valuation at Vertical Research
Vertical Research analyst Chip Dillon upgraded Ball Crop to Buy from Hold citing the recent drop in shares and maintained a $44 price target
01/17/18
SBSH
01/17/18
UPGRADE
Target $45
SBSH
Buy
Ball Corp. upgraded to Buy from Neutral at Citi
Citi analyst Anthony Pettinari upgraded Ball Corp. to Buy and raised his price target for the shares to $45 from $43. The analyst views the recent selloff as overdone and sees an attractive entry point at current share levels. He also sees a "compelling setup" into Ball's Q4 results.
01/17/18
JPMS
01/17/18
DOWNGRADE
Target $30
JPMS
Underweight
Silgan Holdings downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tyler Langton downgraded Silgan Holdings (SLGN) to Underweight and lowered his price target for the shares to $30 from $32. The analyst cites valuation for the downgrade, noting Silgan is trading at a premium to Crown Holdings (CCK) on a free cash flow yield basis despite its lower margins and growth potential. The analyst names Berry Global (BERY), Ball Corp. (BLL) and Crown Holdings his top Packaging picks for 2018. He sees the sector's earnings growth rebounding this year.
02/11/18
KEYB
02/11/18
UPGRADE
KEYB
Sector Weight
Ball Corp. upgraded to Sector Weight from Underweight at KeyBanc
KeyBanc analyst Adam Josephson upgraded Ball Corp. to Sector Weight citing valuation following the Q4 beat.
CBS CBS
$54.65

1 (1.86%)

05/15/18
05/15/18
UPGRADE
Target $65

Outperform
CBS upgraded to Outperform at Bernstein
As previously reported, Bernstein upgraded CBS (CBS) to Outperform from Market Perform, with a $65 price target, as it views the probability of a CBS-Viacom (VIAB) re-merger as close to zero, for many years to come. While the firm remains very concerned about the health of TV networks, generally, and has plenty of specific concerns about CBS, it believes that as a stand-alone entity it has the cleanest story in all of media. Bernstein reiterates an Underperform rating on Viacom.
05/15/18
SBSH
05/15/18
NO CHANGE
Target $66
SBSH
Buy
Citi drops likelihood of CBS-Viacom merger to 25% from 50%
Citi analyst Jason Bazinet dropped his likelihood of a CBS (CBS), Viacom (VIAB) merger to 25% from 50% after CBS filed a Delaware lawsuit asking for a restraining order to prevent Shari Redstone from interfering with a special CBS board meeting. The analyst now sees a lower chance of CBS acquiring Viacom. As such, he increased his price target for CBS shares to $66 from $61 and lowered his price target for Viacom shares to $29 from $30.
05/07/18
SPHN
05/07/18
NO CHANGE
Target $58
SPHN
Equal Weight
CBS-Viacom deal could work at Class B shareholders' expense, says Stephens
Stifel analyst Kyle Evans contends that CBS (CBS) posted the kind of quarter that should fundamentally separate the company from many media peers. However, he said there is no more clarity following its report on whether its Class A shareholders will push for a combination with Viacom (VIAB) that "undermines Class B holders." Evans lowered his price target on CBS to $58 from $64 and maintains an Equal Weight rating on the stock.
05/15/18
BERN
05/15/18
UPGRADE
BERN
Outperform
CBS upgraded to Outperform from Market Perform at Bernstein
UAL United Continental
$67.28

0.64 (0.96%)

03/09/18
JPMS
03/09/18
NO CHANGE
JPMS
JPMorgan sees Airlines raising Q1 outlooks at next week's conference
JPMorgan analyst James Baker believes several Airlines will raise their Q1 guidance at his firm's Aviation, Transportation and Industrials Conference next week. He expects near-term consensus estimates to move higher for the airlines coming out of the presentations, particularly for United Continental (UAL). The analyst recommends increasing exposure to the sector ahead of the conference. He raised his estimates for United the most, taking his Q1 earnings per share forecast up to 32c from 3c. Other names in the space include American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU) and Southwest (LUV).
05/03/18
STFL
05/03/18
NO CHANGE
STFL
Stifel says Alaska, JetBlue may be targets if 'Big 4' think they can consolidate
Stifel analyst Joseph DeNardi said in a note to investors prior to the open that the proposed merger of Sprint (S) and T-Mobile (TMUS), and the related approval process, is the first major test of the Trump administration's view on consolidation. Depending on how this case plays out, management teams at the "Big 4" airlines would have significant interest in acquiring Alaska Air (ALK) or JetBlue (JBLU) if they think they could be successful in doing so, he contends. He believes the current consensus in the industry is that Alaska will serve as buyer and consolidator within its segment, but should the Big 4 believe that they could be permitted to be buyers, the M&A outlook would likely change, DeNardi tells investors.
04/11/18
IMPC
04/11/18
NO CHANGE
IMPC
Spirit Airlines Q1, FY18, FY19 EPS estimates raised at Imperial Capital
Imperial Capital analyst Megan Barnett said that with "current valuations fully reflecting the competitive situation with United (UAL)," investors should look to Spirit Airlines (SAVE) and its ancillary revenue growth. The analyst raised her Q1 EPS estimate for Spirit to 45c from 35c, her FY18 EPS estimate to $3.30 from $2.75, and her FY19 EPS estimate to $4.20 from $4.00. Barnett maintained an Outperform rating and $52 price target on Spirit Airlines shares. The price target is 48% above Spirit's recent share price.
04/30/18
JPMS
04/30/18
UPGRADE
Target $46
JPMS
Overweight
Spirit Airlines upgraded to Overweight from Underweight at JPMorgan
JPMorgan analyst Jamie Baker double upgraded Spirit Airlines (SAVE) to Overweight from Underweight with an unchanged price target of $46. The stock closed Friday up 9c to $35.49. Down 20% year-to-date, Spirit's shares are the sector's worst performer, Baker tells investors in a research note. The selloff took place despite the removal of the pilot overhang and the unexpected lease-to-purchase swap "which negates much of the pilot impact on CASM," the analyst adds. Further, Baker now sees a "more plausible" path back to the $4 earnings per share range next year. The analyst this morning also downgraded shares of JetBlue (JBLU) to Neutral. He still likes the risk/reward profile on the "Big Three" relative to the discounters, and maintains Overweight ratings on American Airlines (AAL), Delta Air Lines (DAL) and United Continental (UAL).
C Citi
$72.78

0.15 (0.21%)

04/17/18
BMOC
04/17/18
NO CHANGE
Target $34
BMOC
Market Perform
Bank of America is the best of the 'big four' U.S. banks, says BMO Capital
BMO Capital analyst James Fotheringham kept his Market Perform rating and $34 price target on Bank of America (BAC) after its in-line Q1 earnings but raised his FY18 EPS view to $2.62 from $2.59 and FY19 view to $3.18 from $3.12. Fotheringham says than in contrast, he lowered earnings forecasts for JPMorgan (JPM), Wells Fargo (WFC), and Citigroup (C) because of higher costs and lower revenues, but Bank of America's better than expected net interest income rise justifies his view of the bank as the "best of the bunch". The analyst also notes the bank's more favorable valuation trading at a below-average two-year-forward P/E multiple despite his forecast of double the core earnings growth rate of Bank of America's peers.
04/11/18
HSBC
04/11/18
UPGRADE
Target $85
HSBC
Buy
Citi upgraded to Buy from Hold at HSBC
HSBC analyst Alevizos Alevizakos upgraded Citi to Buy and raised his price target for the shares to $85 from $82. The analyst sees improved profitability in the near-term, driven by U.S. dollar depreciation and tax reform, re-rating the shares higher. He believes the market is not fully appreciating Citi's leading credit card franchise and its growth prospects in Mexico.
04/11/18
04/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Citi (C) upgraded to Buy from Hold at HSBC with analyst Alevizos Alevizakos saying he sees improved profitability in the near-term, driven by U.S. dollar depreciation and tax reform, re-rating the shares higher. 2. BHP Billiton (BHP) upgraded to Buy from Hold at Deutsche Bank with analyst Liam Fitzpatrick saying the shares offer compelling value at current levels. 3. Mattel (MAT) upgraded to Hold from Underperform at Jefferies with analyst Stephanie Wissink saying the company's near-term risks are largely known and priced into the shares. 4. AeroVironment (AVAV) upgraded to Buy from Hold at Stifel with analyst Joseph DeNardi saying he sees the company benefiting from tailwinds including an improving defense budget environment, a heightened global threat environment, and "as strong a pipeline of opportunities" as he has seen in ten years. 5. Helmerich & Payne (HP) upgraded to Market Perform from Underperform at Wells Fargo with analyst Judson Bailey citing strength in the land rig market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/18
04/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying he believes the company will continue to take share in first-line lung cancer, driven by positive KN-189 and KN-042 data. 2. Acuity Brands (AYI) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he believes the stock is finally trading at a "reasonable valuation based on reasonable expectations." 3. AMD (AMD) upgraded to Buy from Hold at Stifel with analyst Kevin Cassidy citing valuation and the company's margin expansion potential. 4. Tiffany (TIF) upgraded to Buy from Hold at Loop Capital with analyst Laura Champine saying her initial meeting with the company's new CEO Alessandro Bogliogo added to her confidence. 5. Citi (C) and Wells Fargo (WFC) were upgraded to Buy from Neutral at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
OCN Ocwen
$4.58

-0.03 (-0.65%)

06/20/17
WEDB
06/20/17
DOWNGRADE
WEDB
Neutral
New Residential downgraded on downward rates, regulatory worries at Wedbush
As noted earlier, before the market opened, Wedbush downgraded New Residential (NRZ) to Neutral from Outperform Analyst Jason Weaver downgraded the stock based on falling interest rates and his belief that the CFPB and Florida's attorney general could seek to sue New Residential as part of their lawsuit against Ocwen (OCN). The analyst does not expect New Residential to be hurt by any such lawsuits, but he says that they would create headline risk for the company and could delay the closing of its deal with Ocwen. Target to $16.50 from $17.
05/16/17
PIPR
05/16/17
NO CHANGE
Target $18
PIPR
Overweight
New Residential target raised to $18 after CEO meeting at Piper Jaffray
Piper Jaffray analyst Kevin Barker raised his price target for New Residential Investment (NRZ) after hosting meetings with the company's CEO Michael Nierenberg. The analyst has increased confidence that the Ocwen (OCN) mortgage servicing rights deal will be "meaningfully accretive" to New Residential and provide support for a higher dividend in the future. Barker reiterates an Overweight rating on the shares.
03/07/18
SPHN
03/07/18
NO CHANGE
Target $55
SPHN
Overweight
PHH-Ocwen deal may have 'positive ripple effect' on Black Knight, says Stephens
After Ocwen (OCN) recently announced a deal to acquire PHH Corporation (PHH), Stephens analyst John Campbell said he believes the deal could have a "positive ripple effect" on Black Knight (BKI), which has an MSP deal with Ocwen Loan Servicing, in the second half of this year if not perhaps sooner. He thinks a faster go-live with Ocwen could help drive quarterly beats and guidance raises for Black Knight, Campbell tells investors. He keeps an Overweight rating and $55 price target on Black Knight shares.
ASH Ashland
$74.43

-0.25 (-0.33%)

03/26/18
LBOW
03/26/18
UPGRADE
LBOW
Buy
Ashland upgraded to Buy from Neutral at Longbow
03/27/18
BMOC
03/27/18
INITIATION
Target $82
BMOC
Outperform
Ashland initiated with an Outperform at BMO Capital
BMO Capital analyst John McNulty started Ashland with an Outperform rating and $82 price target.
03/23/18
03/23/18
UPGRADE
Target $79

Outperform
Ashland upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Christopher Parkinson upgraded Ashland to Outperform from Neutral as he now feels the story embodies a favorable, asymmetric risk/reward ratio. The analyst also raised his price target on the shares to $79 from $74.
05/03/18
KEYB
05/03/18
NO CHANGE
Target $87
KEYB
Overweight
Ashland price target raised to $87 from $80 at KeyBanc
KeyBanc analyst Michael Sison raised his price target for Ashland to $87 from $80 following "solid" results. The analyst reiterates an Overweight rating on the shares.
HRG HRG Group
$11.42

-0.48 (-4.03%)

SHPG Shire
$170.05

1.67 (0.99%)

04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Outperform
Wells says Allergan investors likely 'relieved and confused' by Shire news
Wells Fargo analyst David Maris believes Allergan (AGN) investors will be "both relieved and confused" by the company's announcement that it was considering a bid for Shire (SHPG) being following approximately four hours later by another announcement saying that it does not intend to make an offer for Shire. After catching up with Allergan, Maris does not think the turn of events reflects a confusion or flip-flopping, but rather was the result of disclosures required by UK takeover law, and "don't reflect anything other than Allergan being caught at a bad time." He maintains an Outperform rating on Allergan shares.
04/19/18
WELS
04/19/18
NO CHANGE
Target $245
WELS
Outperform
Allergan selloff on potential Shire bid understandable, says Wells Fargo
Wells Fargo analyst David Maris believes the selloff today in shares of Allergan (AGN) on news the company is considering a bid for Shire (SHPG) is understandable. Many believe Allergan was in the process of trimming, not bulking up, Maris tells investors in a research note. He believes that if CNBC's subsequent report is true and Allergan won't be making a bid, the "about-face would be an incredible turn given Allergan's press release came out just a couple hours earlier." Further, the analyst thinks investors are now left wondering what type of disruption another major integration could mean for a company that has already had significant organizational change. Maris has an Outperform rating on Allergan with a $245 price target. The stock in afternoon trading is down 4% to $159.36.
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
ALLY Ally Financial
$27.15

0.34 (1.27%)

03/27/18
UBSW
03/27/18
INITIATION
UBSW
Buy
Ally Financial initiated with a Buy at UBS
UBS analyst Eric Wasserstrom initiated Ally Financial with a Buy rating and $33 price target. Wasserstrom believes that Ally's asset mix and funding structure should drive revenue growth, which will improve return on assets and drive price-earnings expansion.
04/09/18
SPHN
04/09/18
UPGRADE
SPHN
Equal Weight
Ally Financial upgraded to Equal Weight from Underweight at Stephens
04/09/18
04/09/18
UPGRADE

Equal Weight
Ally Financial, Discover upgraded to Equal Weight on valuation at Stephens
As previously reported, Stephens analyst Vincent Caintic upgraded Ally Financial (ALLY) and Discover (DFS), both to Equal Weight from Underweight, as he does not think shares of either have downside from their current levels. He notes Ally shares are down 9% year-to-date, while Discover shares have declined 9% in 2018 as well. Still, he is concerned about U.S. consumer credit broadly and continues to think Discover will underperform relative to the credit card space and that Ally will underperform other auto lenders, Caintic tells investors. He set a $29 price target on Ally shares and a $73 target on Discover.
04/09/18
04/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he sees room for positive earnings revisions for GM, Ford (F) and Fiat Chrysler (FCAU) as investors better understand the impact on U.S. pick-up truck sales from a potential passage of a U.S. infrastructure bill. 2. TD Ameritrade (AMTD) upgraded to Buy from Neutral at BofA/Merrill with analyst Michael Carrier saying he views TD Ameritrade's near-term outlook as attractive given healthy new net asset growth, higher interest rates, and strong DARTs. 3. Comerica (CMA) upgraded to Outperform from Neutral at Wedbush with analyst Peter Winter saying he sees several levers that should drive above average earnings per share growth over the next two years, including margin expansion, potential resumption of loan growth, and above average capital returns. 4. Agilent (A) upgraded to Buy from Neutral at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools. 5. Discover (DFS) and Ally Financial (ALLY) were upgraded to Equal Weight from Underweight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WFC Wells Fargo
$55.12

0.64 (1.17%)

04/16/18
BARD
04/16/18
NO CHANGE
Target $62
BARD
Outperform
Lower expectations limit Wells Fargo downside, says Baird
Baird analyst David George said Wells Fargo reported messy Q1 results, but lowered expectations should limit the downside in the shares. The analyst said core fees were weak, but expenses were in line as was loan growth. George maintained his Outperform rating and $62 price target on Wells Fargo shares.
04/16/18
NOMU
04/16/18
NO CHANGE
Target $68
NOMU
Buy
Wells Fargo earnings underwhelming, but not a value trap, says Nomura
Nomura Instinet analyst Bill Carcache lowered his price target for Wells Fargo to $68 from $72 saying Friday's earnings results were "underwhelming" as the company reported softer revenue growth. The analyst, however, continues to believe that shares of Wells Fargo are "not a value trap." Shareholders "able to weather the current storm" will be rewarded with 10% earnings growth, mid- to high-teens return on tangible equity, and a multiple rerating when the market regains confidence, Carcache tells investors in a research note. He keeps a Buy rating on the shares.
04/30/18
04/30/18
UPGRADE

Outperform
Wells Fargo double upgraded to Outperform at Macquarie
Macquarie analyst David Konrad upgraded Wells Fargo to Outperform from Underperform with a $61 price target citing attractive valuation, low expectations, and near-term catalysts. Konrad said valuation and consensus estimates have finally come down and said shares are trading at 11.3x his 2019 "stressed earnings" estimate, compared to super regionals trading at 12.3x. The analyst expects low expense guidance at the upcoming investor day and passing CCAR in June to serve as positive catalysts for shares.
FB Facebook
$184.05

-2.63 (-1.41%)

05/11/18
BNCH
05/11/18
NO CHANGE
Target $182
BNCH
Buy
IAC price target raised to $182 from $176 at Benchmark
Benchmark analyst Daniel Kurnos raised his price target on IAC (IAC) to $182 from $176 after its "strong" quarter, which he said was "headlined by blowout revenue and earnings" from Match (MTCH) and continued strong growth at Angi Homeservices (ANGI). He believes risk to IAC from a Facebook (FB) dating challenge seems largely factored in at current levels, Kurnos added.
05/10/18
BMOC
05/10/18
NO CHANGE
Target $45
BMOC
Outperform
Match Group price target lowered to $45 from $49 at BMO Capital
BMO Capital analyst Daniel Salmon lowered his price target on Match Group (MTCH) to $45, citing the recent sell-off in the stock price after the Facebook (FB) announcement that it is entering into the online dating market. Salmon keeps his Outperform rating however, stating that the valuation discount is too great because he does not expect a "material disruption" to Tinder's use of the Facebook login. The analyst adds that 75% of Tinder users decline to login through Facebook, suggesting that people prefer to keep some space between their social and dating lives.
05/10/18
UBSW
05/10/18
UPGRADE
Target $48
UBSW
Buy
Match Group upgraded to Buy at UBS
As previously reported, UBS analyst Eric Sheridan upgraded Match Group (MTCH) to Buy from Neutral. The analyst said the recent risks and fears of competition from Facebook (FB) are priced in and its solid Q1 results show the trends for its core brands remain intact. Sheridan maintained his $48 price target on Match Group shares.
05/10/18
DBAB
05/10/18
NO CHANGE
Target $43
DBAB
Buy
Match Group price target raised to $43 from $33 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Match Group (MTCH) to $43 and keeps a Buy rating on the shares. The company's "strong" Q1 results were "overwhelmed' by concerns over Facebook (FB), Walmsley tells investors in a research note. He believes multiple expansion could remain challenged until investors have visibility into Facebook's product and adoption trends.
AER AerCap
$55.35

-0.13 (-0.23%)

12/08/17
SBSH
12/08/17
INITIATION
Target $57
SBSH
Neutral
AerCap initiated with a Neutral at Citi
Citi analyst Kevin Crissey starts AerCap Holdings with a Neutral rating and $57 price target. The analyst thinks investors should wait for a better entry point into the shares.
03/14/18
MACQ
03/14/18
INITIATION
Target $62
MACQ
Outperform
AerCap initiated with an Outperform entering growth phase, says Macquarie
Macquarie analyst Susan Donofrio initiated AerCap with an Outperform and $62 price target. Donofrio believes the company is entering a new growth phase, with scale and relationships that give it a competitive advantage, and will maintain a share-holder friendly capital allocation strategy.
12/15/17
WELS
12/15/17
NO CHANGE
Target $62
WELS
Outperform
AerCap book value can hit $100 per share in 2022, says Wells Fargo
Wells Fargo analyst Gary Liebowitz estimates AerCap can sustain at least 12% annual book value-per-share growth over the next five years via a mix of revenue growth and accretive share buybacks. As such, the company can ultimately achieve a $100 per share book value at the end of 2022, Liebowitz tells investors in a research note. He views the current valuation as "very attractive" and keeps an Outperform rating on AerCap with a $62 price target.
03/13/18
MACQ
03/13/18
INITIATION
Target $62
MACQ
Outperform
AerCap initiated with an Outperform at Macquarie
Macquarie initiated AerCap with an Outperform and $62 price target.
GOOGL Alphabet Class A
$1,088.54

-18.03 (-1.63%)

05/01/18
ROTH
05/01/18
NO CHANGE
Target $8
ROTH
Buy
Google provides validation to Fitbit digital therapeutics thesis, says Roth Capital
Roth Capital analyst Scott Searle notes that Fitbit (FIT) announced a Google (GOOG; GOOGL) relationship that begins with costs and scale and extends to collaboration and innovation around wearables and its resulting data. The analyst believes Google adds performance and efficiencies as well validates Fitbit's emerging digital therapeutics presence. Searle reiterates a Buy rating and $8 price target on Fitbit's shares.
05/09/18
JPMS
05/09/18
NO CHANGE
JPMS
Overweight
Broadcom co-designed Google's third generation AI processor, says JPMorgan
Google (GOOG, GOOGL) yesterday as its developer conference introduced its third generation deep learning/artificial intelligence processor chip called the Cloud Tensor Processor Unit, JPMorgan analyst Harlan Sur tells investors in a research note. The analyst believes the TPU3 chip was co-designed by Broadcom (AVGO). Further, and just as important, Sur believes Broadcom has won, and is already working with Google on its fourth generation TPU4 processor chip using 7nm manufacturing technology. Broadcom remains the analyst's top pick in semiconductors. He reiterates an Overweight rating on the shares.
05/10/18
MSCO
05/10/18
NO CHANGE
Target $93
MSCO
Equal Weight
Walmart deal for Flipkart more dilutive than anticipated, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman noted that news reports heading up to Walmart's (WMT) deal for a majority stake in Flipkart had predicted a $12B transaction for about 60% of a business generating operating losses in the $1B range. However, the higher than expected magnitude of losses Walmart would absorb in India significantly raises the stakes on the trajectory of its U.S. business and clouds the near-term path, he said. He also questions why the company is investing outside the U.S. market, stating that it could have instead accelerated its third-party marketplace infrastructure, stepped up its partnership with Google Home (GOOG) to better compete with Amazon's (AMZN) Alexa, or intensified domestic investments in price and fulfillment. However, he does add that the deal prevents Amazon, for now, from building an "insurmountable" advantage in the important Indian market. Gutman lowered his price target on Walmart to $93 from $99 after the deal was more dilutive than anticipated and keeps an Equal Weight rating on the shares.
05/01/18
MSCO
05/01/18
NO CHANGE
Target $4
MSCO
Underweight
Fitbit Q1 results likely to be light, says Morgan Stanley
Morgan Stanley analyst Yuuji Anderson said his channel checks found inventory drawdown of Fitbit (FIT) products in-line with typical seasonality, but he noticed limited restocking of Charge 2 and the Alta HR at many retail locations. He thinks the market is prepared for a slight miss to Q1 estimates, but faster declines in legacy products will jeopardize management's FY18 revenue target. He thinks it will become increasingly apparent as the year progress that revenues won't stabilize and cash burn will resume, Anderson tells investors. The analyst, who said the Google (GOOGL) collaboration "does not point to acquisition potential," keeps an Underweight rating and $4 price target on Fitbit shares.
AMCX AMC Networks
$56.81

-0.13 (-0.23%)

05/11/18
05/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kohl's (KSS) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Binetti saying he sees first quarter same store sales risk due to cold weather damaging industry traffic and Kohl's being more weather sensitive than its peers, and slightly lowered his Q1 EPS estimate on the stock. 2. Symantec (SYMC) downgraded to Sell from Neutral at MoffettNathanson, to Equal Weight from Overweight at Barclays and First Analysis, to Perform from Outperform at Oppenheimer, and to Neutral from Buy at BTIG, to Neutral from Outperform at Macquarie, and to Neutral from Overweight at Piper Jaffray. 3. AMC Networks (AMCX) downgraded to In Line on valuation at Evercore ISI with analyst David Joyce citing valuation. 4. L Brands (LB) downgraded to Neutral from Overweight at Atlantic Equities. 5. Presidio (PSDO) downgraded to Sector Perform from Outperform at RBC Capital and to Market Perform from Outperform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/11/18
RBCM
05/11/18
NO CHANGE
Target $65
RBCM
Sector Perform
AMC Networks price target raised to $65 from $57 at RBC Capital
RBC Capital analyst Steve Cahall raised his price target on AMC Networks to $65 and kept his Sector Perform rating after its Q1 earnings beat. The analyst says content licensing revenue outperformed, but advertising remains a risk.
05/11/18
GABE
05/11/18
UPGRADE
GABE
Buy
AMC Networks upgraded to Buy from Hold at Gabelli
Gabelli upgraded AMC Networks to Buy saying it remains an excelling company with opportunities to leverage its recent programming momentum into increased advertising and affiliate fees. The firm's analyst believes current valuation provides a margin of safety to justify adding to positions.
05/11/18
05/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Overweight from Neutral at JPMorgan with analyst Philip Cusick saying after a meeting with CEO Lowell McAdam, he has a better understanding that Verizon's "organic approach to wireless has the company on an increasingly stable footing." 2. Mosaic (MOS) upgraded to Outperform from Sector Perform at RBC Capital with analyst Andrew Wong saying that it is "hard to ignore the improving undercurrents in both phosphate and potash markets." 3. Ultragenyx (RARE) upgraded to Overweight from Equal Weight at Barclays with analyst Gena Wang saying she thinks a higher price target for Crysvita could drive upside to revenue growth expectations. 4. U.S. Bancorp (USB) upgraded to Buy from Neutral at Citi with analyst Keith Horowitz saying now is an opportune time to build positions in the stock after three years of significant underperformance. 5. AMC Networks (AMCX) upgraded to Buy from Hold at Gabelli with the firm saying it remains an excelling company with opportunities to leverage its recent programming momentum into increased advertising and affiliate fees. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FDC First Data
$19.58

-0.06 (-0.31%)

04/30/18
CHLM
04/30/18
NO CHANGE
Target $30
CHLM
Buy
First Data price target raised to $30 from $25 at Craig-Hallum
Craig-Hallum analyst Brad Berning raised his price target for First Data to $30 following this morning's Q1 results. The analyst keeps a Buy rating on the shares.
05/01/18
CHLM
05/01/18
NO CHANGE
Target $30
CHLM
Buy
First Data price target raised to $30 from $25 at Craig-Hallum
Craig-Hallum analyst Bradley Berning raised his price target for First Data to $30 from $25, citing the quarterly beat from stronger underlying organic growth. The analyst reiterates a Buy rating on the shares.
04/24/18
MZHO
04/24/18
INITIATION
Target $19
MZHO
Buy
First Data initiated with a Buy at Mizuho
Mizuho analyst Thomas McCrohan started First Data Corporation with a Buy rating and $19 price target. The recovery within the company's core North American merchant processing segment is underway, McCrohan tells investors in a research note. He sees the unit, which represents 48% of total segment revenue, returning to mid-single digit organic revenue growth in 2019. The analyst also thinks First Data's continued deleveraging will eventually lead to a credit upgrade.
04/24/18
04/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. First Data (FDC) initiated with a Buy at Mizuho. 2. Allergan (AGN) resumed with a Buy at Citi. 3. Alder Biopharmaceuticals (ALDR) initiated with a Neutral at Goldman Sachs. 4. ConvergeOne (CVON) initiated with an Outperform at Cowen. 5. Aeglea BioTherapeutics (AGLE) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MSFT Microsoft
$96.46

-1.58 (-1.61%)

05/10/18
FBCO
05/10/18
NO CHANGE
Target $115
FBCO
Outperform
Microsoft continues to leverage penetration in enterprise, says Credit Suisse
Credit Suisse analyst Michael Nemeroff says that Microsoft continues to leverage its existing and deep penetration in the enterprise to further distance itself among its technology peers by incorporating AI and ML into its dominant suite of productivity applications. The analyst reiterates an Outperform rating and $115 price target on the shares.
05/15/18
NEED
05/15/18
NO CHANGE
Target $49
NEED
Buy
Mimecast price target raised to $49 from $46 at Needham
Needham analyst Alex Henderson raised his price target on Mimecast (MIME) to $49 and kept his Buy rating after its "strong" Q4 results and initial FY19 guidance. The analyst notes that the wider than expected loss was in part due to the costs around the company's move to Lexington headquarters. Henderson adds that the upcoming quarter will be the first under the ASC 606 model, which should weigh on revenues but also add "solidly" to operating margins. The analyst is also positive on Mimecast's expansion in Europe following a "smooth" build-out in Germany, while its partnership with Microsoft (MSFT) is not changing despite the comments made regarding security around Office 365.
04/27/18
JPMS
04/27/18
UPGRADE
Target $110
JPMS
Overweight
JPMorgan upgrades Microsoft to Overweight with $110 price target
JPMorgan analyst Mark Murphy upgraded Microsoft to Overweight from Neutral and raised his price target for the shares to $110 from $94 following last night's Q3 results. The stock in premarket trading us up 4%, or $3.68, to $97.94. The global movement toward multi-cloud architectures will benefit Microsoft's Azure, Murphy tells investors in a research note. Further, he believes the company's "linkage to large digital transformation initiatives" and favorable positioning for hybrid cloud architectures create potential for additional upside.

TODAY'S FREE FLY STORIES

KORS

Michael Kors

$68.63

0.25 (0.37%)

, LULU

Lululemon

$106.18

-0.19 (-0.18%)

11:07
05/26/18
05/26
11:07
05/26/18
11:07
Periodicals
Dollar Tree looks interesting, Barron's says »

Next week, another 20…

KORS

Michael Kors

$68.63

0.25 (0.37%)

LULU

Lululemon

$106.18

-0.19 (-0.18%)

GME

GameStop

$12.64

-0.1 (-0.78%)

DLTR

Dollar Tree

$95.23

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 12

    Jun

  • 14

    Jun

  • 26

    Jun

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

, QCOM

Qualcomm

$59.95

0.85 (1.44%)

10:58
05/26/18
05/26
10:58
05/26/18
10:58
Periodicals
Kraft Heinz, J&J among safe, 'solid' dividend stocks, Barron's says »

Kraft Heinz (KHC),…

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

QCOM

Qualcomm

$59.95

0.85 (1.44%)

MRK

Merck

$59.08

-0.03 (-0.05%)

TGT

Target

$71.22

0.28 (0.39%)

OMC

Omnicom

$71.98

-0.1 (-0.14%)

CCL

Carnival

$64.27

0.12 (0.19%)

JNJ

Johnson & Johnson

$121.40

0.06 (0.05%)

MMM

3M

$198.98

-0.38 (-0.19%)

LLY

Eli Lilly

$82.75

0.05 (0.06%)

VLO

Valero

$118.81

-3.06 (-2.51%)

EMR

Emerson

$72.50

-0.77 (-1.05%)

WBA

Walgreens Boots Alliance

$63.52

0.09 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 02

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 19

    Jun

  • 10

    Sep

  • 23

    Oct

MU

Micron

$61.33

-0.15 (-0.24%)

10:48
05/26/18
05/26
10:48
05/26/18
10:48
Periodicals
Micron can solve low valuation, Barron's says »

Micron's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ATUS

Altice USA

$18.50

-0.05 (-0.27%)

10:40
05/26/18
05/26
10:40
05/26/18
10:40
Periodicals
Altice's spinoff could be winning bet, Barron's says »

On June 8, Altice will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

MU

Micron

$61.33

-0.15 (-0.24%)

, XLNX

Xilinx

$69.63

0.88 (1.28%)

10:35
05/26/18
05/26
10:35
05/26/18
10:35
Periodicals
AI revolution just getting started, Barron's says »

Artificial Intelligence…

MU

Micron

$61.33

-0.15 (-0.24%)

XLNX

Xilinx

$69.63

0.88 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:08
05/26/18
05/26
08:08
05/26/18
08:08
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

HMC

Honda

$32.04

-0.34 (-1.05%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$11.51

-0.11 (-0.95%)

GM

General Motors

$38.30

-0.09 (-0.23%)

TM

Toyota

$129.97

-2.47 (-1.87%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAC

Bank of America

$30.16

-0.03 (-0.10%)

C

Citi

$68.42

-0.86 (-1.24%)

GS

Goldman Sachs

$235.05

-1.1 (-0.47%)

JPM

JPMorgan

$110.62

-0.64 (-0.58%)

MS

Morgan Stanley

$53.02

-0.96 (-1.78%)

USB

U.S. Bancorp

$50.54

-0.14 (-0.28%)

WFC

Wells Fargo

$54.91

0.25 (0.46%)

TWTR

Twitter

$33.64

0.11 (0.33%)

AA

Alcoa

$47.92

-1.26 (-2.56%)

CENX

Century Aluminum

$16.27

-0.07 (-0.43%)

AOBC

American Outdoor Brands

$12.53

0.05 (0.40%)

RGR

Sturm, Ruger

$63.10

0.5 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 06

    Jun

  • 20

    Jun

  • 22

    Jun

  • 13

    Jul

  • 27

    Jul

  • 10

    Sep

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 15

    Jul

  • 15

    Oct

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.